国联民生证券表示，创新药或将逐步进入成果兑现阶段。2025年预计是国内创新药授权出海的重要年 份，自2018年"4+7"集采以后，国内企业纷纷开始从仿制药向创新药转型，至今已达7年时间，部分细分 赛道的集采影响已经出清，预计将陆续进入兑现期。 就港股整体表现，近日迎来持续回暖，海外积极信号频现，有望进一步支撑港股反弹走势。 隔夜美国劳工统计局最新公布的数据显示，剔除波动较大的食品和能源后，美国6月CPI较5月上涨 0.2%，同比上涨2.9%，连续5个月低于预期，特朗普随之再度催促美联储降息，港股有望成为美联储开 启宽松周期的主要受益者之一。 7月16日，港股冲高回落，恒指一度涨近4个月高位，尾盘翻绿微跌。港股科技双雄——创新药、科网龙 头走势活跃，科网板块开盘走强，重仓港股互联网龙头的港股互联网ETF（513770）场内价格一度大涨 2.7%，后涨幅有所回落，收涨0.72%，全天成交额9.31亿元，维持高位。快手-W、哔哩哔哩-W涨幅居 前。 板块个股大面积飘红，丽珠医药两位数领涨，最新消息，公司心血管领域1类创新药H001胶囊II期临床 试验患者完成入组；绿叶制药涨超9%，复星医药涨超7%，康方生物再刷新高 ...

当地时间8日，美国总统特朗普威胁对进口药品和铜征收高额关税，其中药品关税可能高达200%。 但将给药企至少一年的时间，在关税生效前将供应链转移回美国。这一举措背后，是美国决策圈面对全 球生物医药，尤其是创新药领域的竞争越来越激烈的危机感和不自信。 前段时间，美国国家新兴生物技术安全委员会（NSCEB）在提交美国国会的报告中指出："中国正 以系统性战略挑战美国生物技术霸权。"以抗体偶联药物（ADC）为例，这种被誉为"魔法子弹"的医药 技术主要用于癌症治疗，能充分反映生物医药产业的技术实力、研发深度和产业竞争力。而在2025年美 国临床肿瘤学会（ASCO）公布的全球184项ADC研究中，中国药企独占89项、占比近半。这份新历史 纪录成为中美博弈中最具象征意义的注脚——曾经由欧美主导的创新药赛道，正在经历"攻守易势"的深 刻变革。 2010年之前，中国药企在全球创新药版图中几乎"隐形"。彼时，美国药企凭借先发优势，牢牢占据 全球创新药市场的领头羊地位，而中国药企收入很大程度上依赖仿制药。到了2015年，中国启动药监改 革成为转折点。得益于吸引大量海外生物医药顶尖人才归国创业与创新积累，国内制药行业上游产业链 逐步形 ...

Core Insights - The company has made significant progress in the development of its innovative drug SYN045, which has received approval for Phase I clinical trials in three different dosages from the National Medical Products Administration of China [1] - The results from the completed clinical trials indicate favorable pharmacokinetic characteristics, enhanced safety, and tolerability compared to similar drugs, supporting the potential for long-term oral administration [1] - The company has submitted a total of 18 invention patents related to the SYN045 project, including 5 international patents and 13 domestic patents, with some already granted [1] Group 1: SYN045 Development - SYN045 is a highly selective PGI2 receptor agonist showing significant anti-pulmonary arterial hypertension effects in animal studies [1] - The company plans to conduct Phase IIa clinical trials based on the final results of Phase I to determine the dose-response relationship and explore efficacy and safety in patients [1] Group 2: Other Drug Developments - The company is developing an innovative anti-epileptic drug targeting the potassium ion channel KCNQ2/3, currently in the compound screening phase and preparing for toxicity evaluation [2] - An innovative drug for diabetic peripheral neuropathic pain is also under development, targeting AAK1, with compound screening currently underway [2] - The company is working on three new drug reformulation projects, with two completing pharmacokinetic-based formulation studies and one planned for IND submission within the year [2]

Core Viewpoint - The pharmaceutical industry in Shenzhen is experiencing unprecedented development opportunities driven by continuous national policy support, with companies like Haizhi Pharmaceutical Group making significant progress in innovative drug development [1][3]. Policy Support and Industry Growth - The national government has enhanced support for the innovative drug industry, establishing a multi-dimensional policy framework that significantly reduces the time for innovative drugs to reach the market [3]. - The establishment of a dynamic adjustment mechanism for the medical insurance catalog has created a green channel for innovative drugs, accelerating the translation of innovative results into clinical applications [3]. - Local governments are also actively responding to national strategies, exemplified by Beijing's plan for the International Pharmaceutical Innovation Park, which aims to provide comprehensive services and expedite product registration processes for innovative drugs [3]. Company Innovations and Achievements - Shenzhen's innovative pharmaceutical companies have made remarkable breakthroughs, with Huadong Medicine developing a product matrix in key areas such as autoimmune diseases and oncology, successfully launching multiple innovative drugs that are now included in the medical insurance catalog [3]. - Betta Pharmaceuticals has established a complete product line targeting key lung cancer markers and is expanding into other therapeutic areas, demonstrating a long-term commitment to oncology innovation [3]. Challenges in Drug Development - Despite positive growth, Shenzhen's innovative pharmaceutical companies face significant challenges, including the complexity of the R&D process, high costs, and low success rates in clinical trials [4]. - The average time for innovative drug development is between 10 to 15 years, with a clinical trial failure rate exceeding 90%, creating substantial financial pressure on companies [4]. - There is a notable shortage of high-end interdisciplinary R&D talent, leading to high training costs and difficulties in fundraising due to the high-risk nature of innovative drug development [4]. Strategic Responses to Challenges - Companies are seeking breakthroughs through differentiated strategies, international expansion, and technological innovation, with Huadong Medicine completing over 30 business development collaborations in the past five years to enhance its R&D capabilities [4][5]. - Betta Pharmaceuticals is focusing on building an innovation ecosystem based on collaboration and shared resources, aiming to foster interaction among talent, projects, information, and funding [5]. - The industry is demonstrating a proactive approach to challenges, emphasizing the importance of innovation and transformation to secure a position in the global pharmaceutical landscape [5].

Group 1 - The pharmaceutical and healthcare sector has experienced a significant rebound, with the Wind Innovation Drug Index showing a year-to-date increase of over 20% and the Hong Kong innovation drug sector leading the market with nearly a 50% rise [1] - The Hong Kong pharmaceutical ETF has become a market focus, with the largest innovation drug ETF reaching a size of 13.59 billion and a net inflow of 230 million over the past five trading days, reflecting a growth of over 6% in the last month [1] - Key stocks in the ETF include WuXi Biologics and BeiGene, which have a research and development expenditure ratio exceeding 15%, with net profit growth and overseas expansion capabilities being the core logic for investment [1] Group 2 - The medical theme fund managed by the China-Europe Medical Fund has stabilized at 40 billion, focusing on innovative drugs, medical devices, and domestic substitution in key industry chains [2] - For instance, Hengrui Medicine is projected to achieve a revenue growth of 22.63% and a net profit growth of 47.28% in 2024, with 17 self-developed innovative drugs contributing nearly 50% of sales revenue [2] - Recent policy changes in China, including the establishment of a drug pricing mechanism and the inclusion of high-value innovative drugs in pilot programs, are expected to support the recovery of the sector [2] Group 3 - The current policy environment emphasizes innovation, contrasting with previous industry shocks caused by generic drug procurement, leading to a faster valuation recovery for companies with sustained R&D capabilities [3] - The China-Europe Medical Fund's report indicates a continued focus on innovative drugs, medical devices, and consumer healthcare, with optimism about breakthroughs in innovative drugs and the recovery of consumer healthcare [3] - The pharmaceutical and healthcare sector is anticipated to benefit from favorable development opportunities as more innovative drugs are successfully launched and the market expands [3]

5月1 5日，恒瑞医药宣布正式启动H股全球公开发售，计划发行2 2 4 , 5 1 9 , 8 0 0股H股（假设超额配售权及发售量调整权未行使），其 中香港公开发售占5 . 5%（1 2 , 3 4 8 , 6 0 0股），国际配售9 4 . 5%（2 1 2 , 1 7 1 , 2 0 0股），发行价区间定为每股4 1 . 4 5—4 4 . 0 5港元。若全额 行使超额配售权及发售量调整权，发行H股最高达2 9 6 , 9 2 7 , 2 0 0股，最高募资额可达1 3 0 . 8亿港元。 这意味着此次恒瑞医药募资额将成为近五年港股医药企业IPO最高募资额。据了解，恒瑞医药H股香港公开发售将于2 0 2 5年5月2 0日 结束，预计于2 2日前（含当日）确定最终发行价，最快或于5月2 3日正式登陆港交所主板，实现"A+H"两地上市。此次发行由摩根 士丹利、花旗及华泰国际担任联席保荐人。 据恒瑞医药方面披露，此次IPO基石投资者包括新加坡政府投资公司（GIC）、景顺（I n v e s c o）、瑞银全球资产管理集团（UBS- GAM）、高瓴资本、博裕资本等。据了解，恒瑞医药基石投资者，按发售价认购或促使 ...

计算等现代化物流新技术，集物料供应、生产、质检、仓储、配发货等功能 于一体的智能化产能供给保障中心建成投运，两条国内领先、西南首屈一指 的现代化智能产线也先后投入运营。随着多个项目的不断投运，全部产线完 成升级且投运后，将可以保障未来一段时间的全产业链系统产能需求，也为 公司在成本控制、质量管控与生产效率提升方面产生极大的内生效益。未 来，公司将按照国家工信部等七部门发布的《医药工业数智化转型实施方案 （2025-2030 年）》要求，积极推进人工智能在生产智造领域的全覆盖，推动 公司向智能化产业方向持续深入迈进，通过新质生产力助力公司实现高质量 发展。感谢您对公司的关注！ 问题三、公司拟投资建设化药生产制剂的生产线，对公司发展有着积极 且深远的影响。作为公司股票投资者，为公司管理层的决策深感欣慰。请问 董事长此次投资建厂对于收购上海汇伦有无联系？收购上海汇伦无论对新天 还是汇伦都是天大好事，董事会近期有没有重启收购计划呢？ 证券代码：002873 证券简称：新天药业 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □分析师会议 | | --- | --- | | ...

Group 1 - In the first quarter, Nanjing's industrial growth rate reached 81.1%, with 30 out of 37 major industries showing year-on-year growth [1][4] - The pharmaceutical manufacturing sector experienced a significant increase of 13.7% in value added [4][3] - The biopharmaceutical industry in Nanjing generated over 210 billion yuan in revenue last year, becoming a key driver of high-quality economic development [3][4] Group 2 - The new high-end daily chemical products project by Jinling Petrochemical, with a total investment of approximately 10 billion yuan, is expected to achieve an annual output value of 23 billion yuan upon completion [5] - The automotive sector saw a retail sales increase of 22.9%, with new energy vehicles experiencing a remarkable growth of 128.7% [5][6] - The investment in emerging manufacturing sectors, such as computer communication and electronic equipment manufacturing, grew by 41.7% year-on-year [8] Group 3 - The establishment of the Nanjing Biopharmaceutical Industry Promotion Office aims to accelerate the transformation of cutting-edge technologies and support the development of innovative drugs and medical devices [4][9] - Nanjing's industrial landscape is characterized by a strong focus on innovation and the cultivation of new growth points, with significant projects underway to enhance production capacity [7][9] - The city is recognized as a national pilot for various advanced manufacturing initiatives, indicating its commitment to becoming a leading industrial hub [7][9]

1 、 《 一季报业绩预告期，重点关注半导体各子行业复苏》摘要 ■ 公司创新药板块收入增长强劲，销售费用率下降（29.79%，同比下降3.41pct），提升了整体盈利 能力。 ■ 卡瑞利珠单抗、吡咯替尼、阿帕替尼、瑞马唑仑 等老产品通过新增适应症持续扩张市场。 ■ GLP-1类创新药 （HRS-7535、HRS9531、HRS-4729）授权 美国Kailera ，预计最高收益 60.35亿 美元 （含首付款1.1亿美元）。 ■ DLL3ADC创新药 （SHR-4849）授权 美国IDEAYA ，预计最高收益 10.45亿美元 （含首付款7500 万美元）。 4 、 《 新消费，"新"在哪里？ 》摘要 ■ 2024年消费者购物的动机中， 悦己 和 彰显个性 的需求分别增长了9%和1%。这一趋势推动了以情 绪为导向的消费市场，如 谷子经济（市场规模1689亿元，同比增长40.6%）和 寺庙经济 （例如好 运莲莲、财神等摆件的成交额同比大幅增长）。 ■ 智能家居 和 数字文旅 等市场的规模持续增长，消费领域也正加速向 线上迁移 ，例如 直播电商 和 即时零售 的快速发展，反映了线下消费向线上转移的趋势。 ■ 年轻 ...